These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20117829)

  • 1. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
    Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles.
    May T; Shoni M; Crum CP; Xian W; Vathipadiekal V; Birrer M; Rosen B; Tone A; Murphy KJ
    Gynecol Oncol; 2013 Mar; 128(3):488-92. PubMed ID: 23253401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
    Ahn G; Folkins AK; McKenney JK; Longacre TA
    Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
    Hunter SM; Anglesio MS; Ryland GL; Sharma R; Chiew YE; Rowley SM; Doyle MA; Li J; Gilks CB; Moss P; Allan PE; Stephens AN; Huntsman DG; deFazio A; Bowtell DD; ; Gorringe KL; Campbell IG
    Oncotarget; 2015 Nov; 6(35):37663-77. PubMed ID: 26506417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
    Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
    PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Manning-Geist BL; Sullivan MW; Zhou Q; Iasonos A; Selenica P; Stallworth C; Liu YL; Long Roche K; Gordhandas S; Aghajanian C; Chi D; O'Cearbhaill R; Grisham RN; Chui MH
    Gynecol Oncol; 2024 Sep; 188():52-57. PubMed ID: 38941962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
    Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas.
    Tung CS; Mok SC; Tsang YT; Zu Z; Song H; Liu J; Deavers MT; Malpica A; Wolf JK; Lu KH; Gershenson DM; Wong KK
    Mod Pathol; 2009 Sep; 22(9):1243-50. PubMed ID: 19525924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of ER/PR expression in ovarian low-grade serous carcinoma.
    Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M
    Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
    Vallejos R; Zhantuyakova A; Negri GL; Martin SD; Spencer SE; Thornton S; Leung S; Lynch B; Qin Y; Chow C; Liang B; Zdravko S; Douglas JM; Milne K; Mateyko B; Nelson BH; Howitt BE; Kommoss FK; Horn LC; Hoang L; Singh N; Morin GB; Huntsman DG; Cochrane D
    J Pathol; 2024 Oct; 264(2):197-211. PubMed ID: 39081243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.